Chr. Hansen Holding A/S and Lonza AG, have signed an agreement to establish a 50/50 joint venture to pioneer the live biotherapeutic products (LBPs) industry and position themselves as a leading contract development and manufacturing partner (CDMO) for biotech and pharma customers. The joint venture will be a 50/50 controlled legal entity that will operate from its headquarters in Basel, Switzerland and have production facilities in Denmark and Switzerland.   The joint venture brings together ...